With Supportive Data, Zealand Looks to NDA for Rare Pediatric Hypoglycemia

Zealand Pharma, a biotech company that creates peptide-based medicines, shared positive top-line results for the second Phase III clinical trial of its congenital hyperinsulinism (CHI) drug, dasiglucagon, in pediatric patients.

The positive data is consistent with Zealand’s first Phase III trial. Though that study ultimately failed to meet the main endpoint, there were optimistic signs under certain conditions. If approved, it would become the first new treatment developed specifically for CHI in over thirty years.

CHI is a rare genetic disease that affects infants and toddlers. Those with CHI have a defect in the gene that produces insulin cells, causing the cells to produce too much insulin and putting the child into a state of hypoglycemia.

Click here to read the full article at BioSpace

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with unmet medical needs. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Comments are closed.